New Taxanes Show Promise Against Cancer
Author Information
Author(s): Ferlini C, Distefano M, Pignatelli F, Lin S, Riva A, Bombardelli E, Mancuso S, Ojima I, Scambia G
Primary Institution: Laboratory of Antineoplastic Pharmacology, Department of Obstetrics and Gynaecology, Università Cattolica Sacro Cuore, Rome, Italy
Hypothesis
The study investigates the effectiveness of novel taxanes that act as both cytotoxic agents and P-glycoprotein inhibitors.
Conclusion
The novel taxanes SB-T-1213 and SB-T-1250 demonstrate significantly higher potency against cancer cells, especially those overexpressing P-glycoprotein.
Supporting Evidence
- The novel taxanes showed up to 400 times higher potency against P-gp positive cells compared to paclitaxel.
- SB-T-1213 and SB-T-1250 were more effective than reference compounds against P-gp negative cells.
- The study found that the new taxanes induce apoptosis and block the cell cycle at G2/M phase.
- The novel taxanes increased the accumulation of beta-tubulin subunits inside cells.
- The Rhodamine 123 assay indicated that these taxanes can inhibit the P-gp efflux pump.
Takeaway
Scientists created new cancer drugs that work better than older ones, especially in tough cases where the old drugs don't work.
Methodology
The study tested the growth inhibition effects of three new taxanes on a panel of seven human cancer cell lines and analyzed cell cycle and apoptosis.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website